There are 2789 resources available
1304P - Interleukin-6 (IL-6) as a potential predictive marker and a desensitizer for immunotherapy response in non-small cell lung cancer
Presenter: Yan Wang
Session: ePoster Display
1305P - Peripheral low-density neutrophils in the response to immunotherapy in untreated non-small cell lung cancer
Presenter: Hugo Arasanz
Session: ePoster Display
1306P - Real-world data of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC (HOT/NJLCG2001)
Presenter: Atsushi Nakamura
Session: ePoster Display
1307P - Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1–positive (TPS ≥50%), advanced NSCLC in Japan
Presenter: Yasushi Goto
Session: ePoster Display
1210P - Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins)
Presenter: Baohui Han
Session: ePoster Display
1211P - Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion
Presenter: Sai-Hong Ou
Session: ePoster Display
1212P - Afatinib for the treatment of NSCLC with uncommon EGFR mutations: An updated database of 1023 cases
Presenter: James Yang Yang
Session: ePoster Display
1213P - Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in a real-life setting (CLEAR)
Presenter: Rami Nassabein
Session: ePoster Display
1214P - High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20
Presenter: Fenneke Zwierenga
Session: ePoster Display
1215P - EGFR-mutated squamous cell lung cancer and its association with outcomes
Presenter: Yang Xia
Session: ePoster Display